Skip to main content Skip to search Skip to main navigation

ICH: ICH Q3C(R8) Guideline for Residual Solvents contains new PDEs

ICH published the revised version (Step 4) of the ICH Q3C(R8) Guideline on Impurities: Guideline for Residual Solvents on 22 April 2021.

The Permitted Daily Exposure (PDE) values for the following substances were added:  

  • 2-Methyltetrahydrofuran (50 mg/day) 
  • Cyclopentyl methyl ether (15 mg/day)  
  • Tertiary butyl alcohol (35 mg/day) 

The PDE values were developed by the relevant Expert Working Group (EWG). On 25 March 2020, ICH already published the document for public consultation under Step 2 (we reported). The values proposed then have been adopted as final and the Step 4 version has not been changed compared to the draft document. This allows implementation to take place in the ICH regions. This ICH process, which is conducted under "Step 5", concludes the revision. 

Toxicity details:  

  • Methyltetrahydrofuran was found to be non-genotoxic in a mutation assay with bacteria, human lymphocytes and rats. No data are available on carcinogenicity. Reproductive toxicity and repeated-dose toxicity were not observed. The product was classified in solvent class 3.  
  • For cyclopentyl methyl ether, no toxicity in humans was found. Likewise, no genotoxic potential was found. Again, no data are available on carcinogenicity. No statements could be made on reproductive and developmental toxicity on the basis of data available to date. The product was classified as a class 2 solvent.  
  • For tertiary butyl alcohol, no genotoxicity was found either. The data on carcinogenicity do not allow any precise conclusions to be drawn with regard to the effect on humans, while changes in the renal tubules were found in rats. No precise statements could be made on reproductive toxicity either, but moderate transient systemic toxicity was found in rats. The product was classified as a class 2 solvent.  

In a revision process, further PDE values are to be gradually added as new toxicological data for solvents become known. 

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

How is a QRM process initiated?

How is a QRM process initiated?

You can view the answer here:
Read more
FDA: Updated Pre-RFD Guidance for Combination Products

FDA: Updated Pre-RFD Guidance for Combination Products

The U.S. FDA has released an updated final guidance on preparing a Pre-Request for Designation (Pre-RFD), replacing the previous 2018 version. The revised document provides new recommendations for interacting with the Office of Combination Products (OCP) and clarifies expectations for Pre-RFD submissions.
Read more
EDQM: 9 Virtual Training Modules on Ph. Eur. and CEPs

EDQM: 9 Virtual Training Modules on Ph. Eur. and CEPs

The EDQM has introduced a modular training programme covering chemically defined active substances and medicinal products. It will take place between 1 and 12 December 2025.
Read more
 Data Integrity and Data Governance

Data Integrity and Data Governance

Data integrity is a key element in the pharmaceutical quality assurance system which has gained importance in recent years, especially from the viewpoint of the authorities. In GxP-regulated companies, managers are responsible for identifying and minimising risks to data integrity (“data governance”).

Read more
EMA Clarifies “Novel or Complex Manufacturing Process” Definition

EMA Clarifies “Novel or Complex Manufacturing Process” Definition

In its Quality of Medicines Q&A – Part 1, the EMA has clarified how “novel or complex manufacturing processes” should be interpreted for variation categories Q.II.b.1 (new/replacement finished product manufacturing site) and Q.II.b.4 (change in batch size).
Read more
EU: Environment Committee Comments on EU Regulation Regarding Critical Medicines

EU: Environment Committee Comments on EU Regulation Regarding Critical Medicines

The Environment Committee of the European Parliament has issued its opinion on the proposed EU Regulation to strengthen the availability of critical medicines. Key recommendations include fast-track permitting, simplified environmental assessments, and support for strategic manufacturing projects to boost EU production capacity.
Read more
Previous
Next